Latest News
FDA grants Breakthrough Therapy designation to Clarity Pharmaceuticals' prostate cancer imaging agent
12 November 2026 - Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals Ltd (ASX: CU6) said on Thursday the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to 64Cu-SAR-bisPSMA for PET imagin...
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
12 November 2026 - Clinical-stage biopharmaceutical company Traws Pharma, Inc. (NASDAQ: TRAW) on Thursday reported final results from a 92-patient Phase 2a study of ratutrelvir, its investigational once-daily oral COVID-19 treatment, and said a bridg...
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
12 November 2026 - Shanton Pharma, a China-based, clinical-stage biotech developing a novel treatment for hyperuricaemia and gout in adults, announced on Wednesday that it has reached an agreement with the European Medicines Agency (EMA) on a Paediat...
MellingMedical partners with CellTivity Scientific to enhance diagnostic cancer sampling for federal healthcare providers
12 November 2026 - MellingMedical, a US-based company that provides veterans with access to healthcare, announced on Wednesday a new strategic relationship with CellTivity Scientific, a US-based company involved in point-of-care disease detection and...
Lilly's Taltz and Zepbound combination delivers sustained psoriatic arthritis improvements at one year
11 November 2026 - Medicine company Eli Lilly and Company (NYSE: LLY) on Wednesday reported 52-week Phase 3b results showing sustained improvements in disease activity, physical function and metabolic outcomes when Taltz (ixekizumab) and Zepbound (ti...